CXCR3 and acute lymphoblastic leukemia: Treatment of T-ALL cells with a CXCR3 antagonist or CRISPR/Cas9-mediated knockout of CXCR3 in T-ALL cells reduced leukemic cell migration to the meningeal stromal cells compared with controls (Figure 6, D and E, and Supplemental Figure 6, A and B).